Pathophysiology, diagnosis and treatment of disseminated intravascular coagulation: An update

Clinical Laboratory

Volumn 51, Issue 11-12, 2005, Pages 633-639

  Franchini, Massimo ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; C REACTIVE PROTEIN; CD14 ANTIGEN; ENDOTOXIN; FIBRINOGEN; FRESH FROZEN PLASMA; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LOW MOLECULAR WEIGHT HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; RECOMBINANT INTERLEUKIN 10; RETINOIC ACID; THROMBIN; THROMBIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TRANEXAMIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD ANALYSIS; BOLUS INJECTION; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; CRYOPRECIPITATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTHROMBIN TIME; REVIEW; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM;

ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; PLATELET TRANSFUSION;

EID: 28844501720     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Bick RL. Disseminated intravascular coagulation. Current concepts of etiology, pathophysiology, diagnosis, and treatment. Hematol Oncol Clin N Am 2003; 17: 149-76.
2. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
3. Levi M, de Jonge E, Van der Poll T, ten Cate H. Disseminated intravascular coagulation: state of the art. Thromb Haemost 1999; 82: 695-705.
4. Levi M, de Jonge E, Meijers J. The diagnosis of disseminated intravascular coagulation. Blood Rev 2002; 16: 217-23.
5. Mammen EF. Disseminated intravascular coagulation (DIC). Clin Lab Sci 2000; 13: 239-45.
6. Carey MJ, Rogers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 1998; 59: 65-73.
7. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004; 124: 567-76.
8. Faust SN, Heyderman RS, Levin M. Disseminated intravascular coagulation and purpura fulminans secondary to infection. Best Pract Res Clin Haematol 2000; 13: 179-97.
9. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-14.
10. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994; 154: 26-34.
11. Dempfle C-E. Coagulation of sepsis. Thromb Haemost 2004; 91: 213-24.
12. Amaral A, Opal SM, Vincent J-L. Coagulation in sepsis. Intensive Care Med 2004; 30: 1032-40.
13. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GA, Sauerwein RW, van der Meer JW, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218: 769-76.
14. Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost 2001; 27: 585-92.
15. Colman RW, Rubin RN. Disseminated intravascular coagulation due to malignancy. Semin Oncol 1990; 17: 172-86.
16. Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 2001; 106: 18-24.
17. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 2001; 27: 593-604.
18. Letsky EA. Disseminated intravascular coagulation. Best Pract Res Clin Obstet Gynaecol 2001; 4: 623-44.
19. Weiner CP. The obstetric patient and disseminated intravascular coagulation. Clin Perinatol 1986; 13: 705-17.
20. Levi M, de Jonge E, van der Poll T. Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Semin Thromb Hemost 2001; 27: 569-75.
21. Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-8.
22. Biemond BJ, Levi M, ten Cate H, Soule HR, Morris LD, Foster DL, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995; 73: 223-30.
23. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-52.
24. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588-92.
25. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-6.
26. Faust SN, Levi M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408-16.
27. De Jorge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-9.
28. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-60.
29. Levi M, van der Poll T, de Jonge E, ten Cate H. Relative insufficiency of fibrinolysis in disseminated intravascular coagulation. Sepsis 2000; 3: 103-9.
30. Biemond BJ, Levi M, Ten Cate H, Van der Poll T, Buller HR, Hack CE, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995; 88: 587-94.
31. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
32. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 639-51.
33. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002; 88: 267-73.
34. van der Poll T, Buller HR, ten Cate H. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Eng J Med 1990; 322: 1622-7.
35. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment and assessment of therapeutic response. Semin Thromb Haemost 1996; 22: 69-88.
36. Rocha E, Paramo JA, Montes R, Panizo C. Acute generalized, widespread bleeding. Diagnosis and management. Haematologica 1998; 83: 1024-37.
37. Yu M, Nardella BS, Pechet L. Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis. Crit Care Med 2000; 28: 1777-80.
38. Wada. H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51: 255-60.
39. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
40. Wada H, Gabazza EC, Asakura H, Koike K, Okamoto K, Maruyama I, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): Diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 2003; 74: 17-22.
41. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society of Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-30.
42. Bakhtiari K, Meijers JCM, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32: 2416-21.
43. Franchini M, Manzato, F. Update on the treatment of the disseminated intravascular coagulation. Hematology 2004; 9: 81-5.
44. Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 2004; 36: 41-9.
45. Riewald M, Riess H. Treatment options for clinically recognized disseminated intravascular coagulation. Semin Thromb Haemost 1998; 24: 53-9.
46. Levi M, de Jonge E, van der Poll T, ten Cate H. Novel approach to the management of disseminated intravascular coagulation. Crit Care Med 2000; 28(Suppl): 20-4.
47. Levi M, de Jonge E, van der Poll T. Therapeutic intervention in disseminated intravascular coagulation: have we made any progress in the last millennium? Blood Rev 2002; 16: 29-34.
48. van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis 2001; 1: 165-74.
49. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29: 90-4.
50. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the Tole of heparin therapy. Blood 1982; 60: 284-7.
51. Hoyle CF, Swisky DM, Freedman L, Hayhoe GFJ. Beneficial effect of heparin in the management of patients with APL. Br J Hematol 1988; 68: 283-9.
52. Goldberg M, Ginsburg D, Mayer R, Stone RM, Maguire M, Rosenthal DS, et al. Is heparin necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987; 69: 187-91.
53. Rodeghiero, F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112-7.
54. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - a multicenter cooperative double blind trial in comparison with heparin. Thromb Haemost 1993; 72: 475-500.
55. Majumdar G. Idiopathic chronic DIC controlled with low-molecular weight heparin. Blood Coagul Fibrinol 1996; 7: 97-8.
56. Pernerstorfer T, Hollenstein U, Hansen JB. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999; 100: 2485-90.
57. Abraham E, Reinhart K, Demeyer I. Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
58. Munoz MC, Montes R, Hermida J, Orbe J, Paramo JA, Rocha E. Effect of the administration of recombinant hirudin and/or tissue-plasminogen activator (T-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits. Br J Haematol 1999; 105: 117-21.
59. Pernerstorfer T, Hollenstein U, Hansen JB, Stohlawetz P, Eichler HG, Handler S, et al. Lepirudin blunts endotoxin-induced coagulation activation. Blood 2000; 95: 1729-34.
60. Schiffer ER, Reber G, De Moerloose P, Morel DR. Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. Crit Care Med 2002; 30: 2689-99.
61. Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Morishita E, et al. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with hematologic malignancy. Blood Coagul Fibrinolysis 1995; 6: 60-4.
62. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-7.
63. Abraham E. Tissue factor inhibition and clinical trials results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28: S31-3.
64. Abraham E, Reinhart K, Svoboda P. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-9.
65. Moons AH, Peters RJ, Cate H, Bauer KA, Vlasuk GP, Buller HR, et al. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 2002; 88: 627-31.
66. De Jonge E, van der Poll T, Kesecioglu J, Levi M. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. Semin Thromb Hemost 2001; 27: 667-74.
67. Giudici D, Baudo F, Palareti G, Ravizza A, Ridolfi L, D'Angelo A. Antithrombin replacement in patients with sepsis and severe shock. Haematologica 1999; 84: 452-60.
68. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Haemost 1998; 24: 27-32.
69. Inthorn D, Hoffman J, Hartl W, Muhlbayer D, Jochum M. Effect of anti-thrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998; 10: 90-6.
70. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacological dosing of antithrombin concentrate for Staphy-lococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997; 89: 4393-401.
71. Fourrier F, Jourdain M, Tournoys A. Clinical trial results with anti-thrombin III in sepsis. Crit Care Med 2000; 28: S38-43.
72. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis: a randomized placebo-controlled, double-blind multicenter trial plus meta-analysis on all randomized, placebo-con-trolled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24: 663-72.
73. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or post-surgical complications: a controlled, double blind, randomized multicenter study. Int Care Med 1998; 24:336-42.
74. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al; KyberSept Trial Study Group. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 1869-78.
75. Gluck T, Opal SM. Advances in sepsis therapy. Drugs 2004; 64: 837-59.
76. Fourrier F. Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review. Crit Care Med 2004; 32: S534-41.
77. Bernard GR, Hartman DL, Helterbrand JD, Fisher CJ. Recom-binant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28-day survival in patients with severe sepsis. Crit Care Med 1998; 27: S4.
78. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al; Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
79. Aoki N, Matsuda T, Saito H, Takatsuki K, Okajima K, Takahashi H, et al; CTC-111-IM Clinical Research Group. A comparative doubleblind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 2002; 75: 540-7.
80. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, et al; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in treatment of severe sepsis patients with multiorgan dysfunction: data from the PROWESS trial. Intensive Care Med 2003; 29: 894-903.
81. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESSS trial. Crit Care Med 2003; 31: 834-40.
82. Levi M, de Jonge E, van der Poll T. Recombinant human activated protein C (Xigris). Int J Clin Pract 2002; 56: 542-5.
83. Pastores SM. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Postgrad Med J 2003; 79: 5-10.
84. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347: 1027-30.
85. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
86. Moscardo F, Perez F, de la Rubia J, Balerdi B, Lorenzo JI, Senent ML, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001; 114: 174-6.
87. Sallah S, Husain A, Nguyen NP. Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2004; 15: 577-82.
88. Avvisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of hemorrhage in acute promyelocytic leukemia. Lancet 1989; 2: 122-4.
89. Norman KE, Cotter MJ, Stewart BJ. Combined anticoagulant and antiselectin treatments prevent lethal intravascular coagulation. Blood 2003; 101:921-8.
90. Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van den Ende A, et al. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 1997; 89: 2701-5.
91. Reinhart K, Waheedullah K. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29: S121-5.
92. Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, Hack CE, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003; 101: 4446-8.
93. Verbon A, Meijers JC, Spek CA. Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis 2003; 187: 55-61.